Patrick is a Principal Investigator and Salk Helmsley Fellow at the Salk Institute for Biological Studies. He received his B.A. from the University of California, Berkeley, as well as A.M. and Ph.D. degrees from Harvard University. Working with Feng Zhang and Xiaowei Zhuang at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT, he contributed to the early development of CRISPR-Cas9 genome engineering technologies for efficient and precise application in eukaryotic cells.
As a lead scientist at Editas Medicine, Patrick also directed preclinical discovery projects to translate these tools for treating human genetic disorders. He was recognized for these contributions in Forbes' 30 Under 30 and the NIH Early Independence Award.
At the Salk, the Hsu lab develops diverse approaches from synthetic biology, genomics, and neuroscience for the high-throughput interrogation and control of transcriptional and epigenetic cell states, particularly for the treatment of neurodegenerative disease and complex genetic disorders.